Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting.

Taku KikuchiNobuhiro TsukadaKodai KunisadaChiaki MatsumotoMoe Nomura-YogoYuki OdaKota SatoTomomi TakeiMizuki OguraYu AbeKenshi SuzukiOsamu HosoyaTadao Ishida

Published in: Annals of hematology (2024)

Keyphrases

multiple myeloma
newly diagnosed
low dose
high dose
type diabetes
skeletal muscle
insulin resistance